Costs and Ethical Issues Related to First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer: Considerations From a Public Healthcare System Perspective
Abstract Metastatic non–small-cell lung cancer is generally not considered to be curable, and the overall 5-year survival rate is less than 1%. Despite this poor prognosis, palliative chemotherapy can increase time and quality of life in the advanced-disease setting. New chemotherapy treatments and...
Saved in:
| Published in: | Clinical lung cancer Vol. 12; no. 6; pp. 335 - 340 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Elsevier Inc
01-11-2011
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Abstract Metastatic non–small-cell lung cancer is generally not considered to be curable, and the overall 5-year survival rate is less than 1%. Despite this poor prognosis, palliative chemotherapy can increase time and quality of life in the advanced-disease setting. New chemotherapy treatments and targeted therapies are available for this stage of disease, but their high costs are an important issue. In this perspective article, we discuss the hospital costs of antitumor drug administration and the ethical principles involved, the roles of drug agencies and oncologists, and relevant current research on these topics. These considerations have been examined from the perspective of a national public healthcare system. |
|---|---|
| AbstractList | Abstract Metastatic non–small-cell lung cancer is generally not considered to be curable, and the overall 5-year survival rate is less than 1%. Despite this poor prognosis, palliative chemotherapy can increase time and quality of life in the advanced-disease setting. New chemotherapy treatments and targeted therapies are available for this stage of disease, but their high costs are an important issue. In this perspective article, we discuss the hospital costs of antitumor drug administration and the ethical principles involved, the roles of drug agencies and oncologists, and relevant current research on these topics. These considerations have been examined from the perspective of a national public healthcare system. Metastatic non-small-cell lung cancer is generally not considered to be curable, and the overall 5-year survival rate is less than 1%. Despite this poor prognosis, palliative chemotherapy can increase time and quality of life in the advanced-disease setting. New chemotherapy treatments and targeted therapies are available for this stage of disease, but their high costs are an important issue. In this perspective article, we discuss the hospital costs of antitumor drug administration and the ethical principles involved, the roles of drug agencies and oncologists, and relevant current research on these topics. These considerations have been examined from the perspective of a national public healthcare system. |
| Author | Quer, Nuria Bosch-Barrera, Joaquim Brunet, Joan |
| Author_xml | – sequence: 1 fullname: Bosch-Barrera, Joaquim – sequence: 2 fullname: Quer, Nuria – sequence: 3 fullname: Brunet, Joan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21816680$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Us1uEzEYXKEi-gMvwAH5xmnDZ2_W2SCEhFZNWylARcrZ8trfUgevndreSrnxDn0A3o0nwasUDhw4fXOYGWlmvtPiyHmHRfGSwowC5W-2M2WtmjGgdAZ8BrB4UpzQZdWUwJdwlHHN6nJRwfy4OI1xC8B4Rdmz4pjRhnLewEnxs_UxRSKdJufp1ihpyVWMI0byBa1MqEnyZGVCTOXaOCQ3AWUa0CXie_IRk4xJJqPIJ-9-_XjYDNLaskVryXp030grncLwlrTeRaMxZGpGZBX8QCS5HjubpZcobbpVMiDZ7GPCgVxjiDtUydzj8-JpL23EF4_3rPi6Or9pL8v154ur9sO6VHMKqZSqA1ZXC9XXgDxn66nmmoHWve7qrqMwr5oKlew7xmvkfE7VUnd931Q9LhlUZ8Xrg-8u-LscP4nBRJWDSId-jGIJDJq6WTSZyQ5MFXyMAXuxC2aQYS8oiGkXsRXTLmLaRQAXeZcsevVoP3YD6r-SP0NkwrsDAXPIe4NBRGUwt6dNyE0I7c3__d__I1fWuGnO77jHuPVjcLk-QUVkAsRm-ozpMSgFmHD1G4rVuKI |
| CitedBy_id | crossref_primary_10_1186_s40064_016_2559_9 crossref_primary_10_1016_j_lungcan_2014_07_010 |
| Cites_doi | 10.1186/1471-2407-9-39 10.7326/0003-4819-136-3-200202050-00012 10.1056/NEJMoa011954 10.1056/NEJMoa0909530 10.1056/NEJMoa1006448 10.1136/bmj.317.7161.771 10.1016/j.lungcan.2009.08.006 10.1016/j.gaceta.2010.05.007 10.1200/JCO.2006.09.6081 10.1016/S0169-5002(10)70135-5 10.1111/j.1524-4733.2008.00401.x 10.2307/3527640 10.1093/annonc/mdf332 10.1378/chest.128.1.452 10.1158/1078-0432.CCR-03-0156 10.1093/annonc/mdn774 10.1097/MCP.0b013e32832b8a5d 10.1634/theoncologist.11-2-90 10.1097/JTO.0b013e3181c4dedb 10.1016/S1470-2045(09)70364-X 10.1056/NEJMoa061884 10.1378/chest.08-2621 10.1016/j.lungcan.2009.11.020 10.1200/JCO.2003.12.046 10.1200/JCO.2009.26.1321 10.1093/annonc/mdh260 10.1200/JCO.2009.23.5622 10.2165/00019053-200927020-00003 10.1093/annonc/mdq194 10.1038/461336a 10.3322/canjclin.57.1.43 10.1200/JCO.2008.18.7658 10.1097/JTO.0b013e3181f77a6a 10.1200/JCO.2007.15.0375 10.1097/JTO.0b013e3181ee820c 10.1097/JTO.0b013e3181e9a00f 10.3816/CLC.2010.n.019 10.1007/s12094-010-0542-4 10.1136/bmj.311.7010.899 10.1200/JCO.2006.09.7915 10.1056/NEJMoa0810699 10.1097/JTO.0b013e3181c6f035 10.1158/1078-0432.CCR-09-0391 10.1093/jnci/djp177 10.1093/jnci/djp472 10.3816/CLC.2009.n.035 10.1378/chest.106.3.861 10.1016/S0169-5002(10)70134-3 10.1200/JCO.2007.12.5435 10.1200/JCO.2009.21.9618 10.1200/JOP.091058 10.1016/S0140-6736(09)60569-9 10.1634/theoncologist.2010-S1-43 |
| ContentType | Journal Article |
| Copyright | Elsevier Inc. 2011 Elsevier Inc. Copyright © 2011 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Elsevier Inc. – notice: 2011 Elsevier Inc. – notice: Copyright © 2011 Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1016/j.cllc.2011.06.007 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Economics |
| EISSN | 1938-0690 |
| EndPage | 340 |
| ExternalDocumentID | 10_1016_j_cllc_2011_06_007 21816680 S1525730411001525 1_s2_0_S1525730411001525 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .FO .XZ .~1 0R~ 1P~ 1~. 29B 4.4 457 4G. 53G 5GY 5VS 6J9 6PF 7-5 8P~ AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXKI AAXUO ABBQC ABFNM ABJNI ABMAC ABMZM ABXDB ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEGXH AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CAG COF DU5 EBS EFJIC EJD EMB EMOBN F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM M41 MET MO0 O-L O9- OAUVE OBH OC~ OHH OO- OVD P-8 P-9 PC. Q38 R2- ROL SDF SEL SES SPCBC SSH SSZ SV3 T5K TEORI UDS Z5R ~G- AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c410t-acb02537cf50e6166f1d6d20ddfdb5bb104383ecafb265e6641c9dbff83fe9203 |
| ISSN | 1525-7304 |
| IngestDate | Fri Oct 25 06:34:40 EDT 2024 Thu Sep 26 18:13:22 EDT 2024 Sat Sep 28 07:49:17 EDT 2024 Fri Feb 23 02:29:01 EST 2024 Tue Oct 15 22:56:49 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Economics Ethics Health care costs Non–small-cell lung cancer Costs |
| Language | English |
| License | Copyright © 2011 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c410t-acb02537cf50e6166f1d6d20ddfdb5bb104383ecafb265e6641c9dbff83fe9203 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 21816680 |
| PQID | 902085878 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_902085878 crossref_primary_10_1016_j_cllc_2011_06_007 pubmed_primary_21816680 elsevier_sciencedirect_doi_10_1016_j_cllc_2011_06_007 elsevier_clinicalkeyesjournals_1_s2_0_S1525730411001525 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-11-01 |
| PublicationDateYYYYMMDD | 2011-11-01 |
| PublicationDate_xml | – month: 11 year: 2011 text: 2011-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical lung cancer |
| PublicationTitleAlternate | Clin Lung Cancer |
| PublicationYear | 2011 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Sandler, Gray, Perry (bib8) 2006; 355 Pirker, Pereira, Szczesna (bib36) 2009; 373 Schiller, Harrington, Belani (bib6) 2002; 346 Gridelli, Maione, Rossi (bib25) 2009; 66 (bib5) 1995; 311 Lynch, Patel, Dreisbach (bib56) 2010; 28 Cobo, Isla, Massuti (bib27) 2007; 25 (bib2) 2010 Fox, Brooks, Kim (bib18) 2008; 14 Mitsudomi, Morita, Yatabe (bib10) 2010; 11 Cassell (bib14) 2000; 30 Patel, Bonomi, Socinski (bib49) 2009; 10 Marino, Pampallona, Preatoni (bib4) 1994; 106 Stanisic, Bischoff, Heigener (bib17) 2010; 69 Stathopoulos, Veslemes, Georgatou (bib54) 2004; 15 Rosell, Danenberg, Alberola (bib28) 2004; 10 (bib34) 2002; 136 Kwak, Bang, Camidge (bib46) 2010; 363 Luce (bib30) 2009; 135 Mao, Qiu, Liao (bib29) 2010; 69 Scagliotti, Parikh, von Pawel (bib53) 2008; 26 Mok, Wu, Thongprasert (bib45) 2009; 361 (bib39) 2010 Rasco, Yan, Xie (bib23) 2010; 5 Prades, Borras (bib40) 2010; 24 Silvestri, Pritchard, Welch (bib32) 1998; 317 Lee, Chertow, Zenios (bib35) 2009; 12 Bischoff, Heigener, Walzer (bib16) 2010; 69 Chouaid, Atsou, Hejblum (bib20) 2009; 27 Montazeri, Tavoli, Mohagheghi (bib33) 2009; 9 Greenberg, Earle, Fang (bib21) 2010; 102 Rosell, Gatzemeier, Betticher (bib52) 2002; 13 Azzoli, Baker, Temin (bib38) 2009; 27 Fojo, Grady (bib37) 2009; 101 Maemondo, Inoue, Kobayashi (bib9) 2010; 362 Meropol, Schulman (bib12) 2007; 25 Owonikoko, Ragin, Belani (bib24) 2007; 25 Tan, Rolski, Grodzki (bib51) 2009; 20 Freedman, Zimmermann (bib31) 2009; 15 Jemal, Siegel, Ward (bib1) 2007; 57 Roila, Herrstedt, Aapro (bib15) 2010; 21 Solomon, Varella-Garcia, Camidge (bib47) 2009; 4 Exposito, Breton, Dominguez (bib44) 2010; 12 Casey, Harb, Bradford (bib48) 2010; 5 Goffin, Lacchetti, Ellis (bib7) 2010; 5 Socinski (bib26) 2010; 11 Jang, Isogai, Mittmann (bib19) 2010; 5 Fossella, Pereira, von Pawel (bib50) 2003; 21 Scagliotti, Novello, von Pawel (bib55) 2010; 28 Neubauer, Hoverman, Kolodziej (bib42) 2010; 6 Cressey (bib13) 2009; 461 Nadler, Eckert, Neumann (bib43) 2006; 11 Wenger, Vespa (bib41) 2010; 15 Yang, Allen, Aubry (bib3) 2005; 128 Morita, Okamoto, Kobayashi (bib11) 2009; 15 Inoue, Kobayashi, Usui (bib22) 2009; 27 Lee (10.1016/j.cllc.2011.06.007_bib35) 2009; 12 Tan (10.1016/j.cllc.2011.06.007_bib51) 2009; 20 Sandler (10.1016/j.cllc.2011.06.007_bib8) 2006; 355 Pirker (10.1016/j.cllc.2011.06.007_bib36) 2009; 373 Scagliotti (10.1016/j.cllc.2011.06.007_bib55) 2010; 28 Owonikoko (10.1016/j.cllc.2011.06.007_bib24) 2007; 25 Luce (10.1016/j.cllc.2011.06.007_bib30) 2009; 135 Lynch (10.1016/j.cllc.2011.06.007_bib56) 2010; 28 Casey (10.1016/j.cllc.2011.06.007_bib48) 2010; 5 Neubauer (10.1016/j.cllc.2011.06.007_bib42) 2010; 6 Scagliotti (10.1016/j.cllc.2011.06.007_bib53) 2008; 26 Gridelli (10.1016/j.cllc.2011.06.007_bib25) 2009; 66 Freedman (10.1016/j.cllc.2011.06.007_bib31) 2009; 15 Maemondo (10.1016/j.cllc.2011.06.007_bib9) 2010; 362 Solomon (10.1016/j.cllc.2011.06.007_bib47) 2009; 4 Exposito (10.1016/j.cllc.2011.06.007_bib44) 2010; 12 Azzoli (10.1016/j.cllc.2011.06.007_bib38) 2009; 27 Cobo (10.1016/j.cllc.2011.06.007_bib27) 2007; 25 Montazeri (10.1016/j.cllc.2011.06.007_bib33) 2009; 9 (10.1016/j.cllc.2011.06.007_bib5) 1995; 311 Stathopoulos (10.1016/j.cllc.2011.06.007_bib54) 2004; 15 Rasco (10.1016/j.cllc.2011.06.007_bib23) 2010; 5 Mitsudomi (10.1016/j.cllc.2011.06.007_bib10) 2010; 11 Mao (10.1016/j.cllc.2011.06.007_bib29) 2010; 69 Marino (10.1016/j.cllc.2011.06.007_bib4) 1994; 106 Cassell (10.1016/j.cllc.2011.06.007_bib14) 2000; 30 Goffin (10.1016/j.cllc.2011.06.007_bib7) 2010; 5 Fossella (10.1016/j.cllc.2011.06.007_bib50) 2003; 21 Silvestri (10.1016/j.cllc.2011.06.007_bib32) 1998; 317 Rosell (10.1016/j.cllc.2011.06.007_bib52) 2002; 13 Wenger (10.1016/j.cllc.2011.06.007_bib41) 2010; 15 Cressey (10.1016/j.cllc.2011.06.007_bib13) 2009; 461 Roila (10.1016/j.cllc.2011.06.007_bib15) 2010; 21 Morita (10.1016/j.cllc.2011.06.007_bib11) 2009; 15 Fox (10.1016/j.cllc.2011.06.007_bib18) 2008; 14 Socinski (10.1016/j.cllc.2011.06.007_bib26) 2010; 11 Nadler (10.1016/j.cllc.2011.06.007_bib43) 2006; 11 Schiller (10.1016/j.cllc.2011.06.007_bib6) 2002; 346 Inoue (10.1016/j.cllc.2011.06.007_bib22) 2009; 27 Prades (10.1016/j.cllc.2011.06.007_bib40) 2010; 24 Greenberg (10.1016/j.cllc.2011.06.007_bib21) 2010; 102 Jang (10.1016/j.cllc.2011.06.007_bib19) 2010; 5 Patel (10.1016/j.cllc.2011.06.007_bib49) 2009; 10 Jemal (10.1016/j.cllc.2011.06.007_bib1) 2007; 57 Stanisic (10.1016/j.cllc.2011.06.007_bib17) 2010; 69 Fojo (10.1016/j.cllc.2011.06.007_bib37) 2009; 101 Meropol (10.1016/j.cllc.2011.06.007_bib12) 2007; 25 (10.1016/j.cllc.2011.06.007_bib39) 2010 Yang (10.1016/j.cllc.2011.06.007_bib3) 2005; 128 (10.1016/j.cllc.2011.06.007_bib34) 2002; 136 Chouaid (10.1016/j.cllc.2011.06.007_bib20) 2009; 27 Mok (10.1016/j.cllc.2011.06.007_bib45) 2009; 361 Rosell (10.1016/j.cllc.2011.06.007_bib28) 2004; 10 Bischoff (10.1016/j.cllc.2011.06.007_bib16) 2010; 69 Kwak (10.1016/j.cllc.2011.06.007_bib46) 2010; 363 |
| References_xml | – volume: 13 start-page: 1539 year: 2002 end-page: 1549 ident: bib52 article-title: Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial publication-title: Ann Oncol contributor: fullname: Betticher – volume: 24 start-page: 416 year: 2010 end-page: 422 ident: bib40 article-title: Prioritization of chemotherapy drugs in the Catalan hospital system: a qualitative case study] publication-title: Gac Sanit contributor: fullname: Borras – volume: 15 start-page: 43 year: 2010 end-page: 48 ident: bib41 article-title: Ethical issues in patient-physician communication about therapy for cancer: professional responsibilities of the oncologist publication-title: Oncologist contributor: fullname: Vespa – volume: 20 start-page: 1249 year: 2009 end-page: 1256 ident: bib51 article-title: Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer publication-title: Ann Oncol contributor: fullname: Grodzki – volume: 28 start-page: 1835 year: 2010 end-page: 1842 ident: bib55 article-title: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer publication-title: J Clin Oncol contributor: fullname: von Pawel – year: 2010 ident: bib39 article-title: Non-small Cell Lung Cancer – volume: 362 start-page: 2380 year: 2010 end-page: 2388 ident: bib9 article-title: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR publication-title: N Engl J Med contributor: fullname: Kobayashi – volume: 15 start-page: 4493 year: 2009 end-page: 4498 ident: bib11 article-title: Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations publication-title: Clin Cancer Res contributor: fullname: Kobayashi – volume: 27 start-page: 6251 year: 2009 end-page: 6266 ident: bib38 article-title: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer publication-title: J Clin Oncol contributor: fullname: Temin – volume: 28 start-page: 911 year: 2010 end-page: 917 ident: bib56 article-title: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099 publication-title: J Clin Oncol contributor: fullname: Dreisbach – volume: 25 start-page: 2747 year: 2007 end-page: 2754 ident: bib27 article-title: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer publication-title: J Clin Oncol contributor: fullname: Massuti – volume: 12 start-page: 493 year: 2010 end-page: 498 ident: bib44 article-title: Controversies on the management of clinical situations with low therapeutic effectiveness in oncology publication-title: Clin Transl Oncol contributor: fullname: Dominguez – volume: 69 start-page: 272 year: 2010 end-page: 278 ident: bib29 article-title: KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies publication-title: Lung Cancer contributor: fullname: Liao – volume: 373 start-page: 1525 year: 2009 end-page: 1531 ident: bib36 article-title: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial publication-title: Lancet contributor: fullname: Szczesna – volume: 5 start-page: 1529 year: 2010 end-page: 1535 ident: bib23 article-title: Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population publication-title: J Thorac Oncol contributor: fullname: Xie – volume: 346 start-page: 92 year: 2002 end-page: 98 ident: bib6 article-title: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer publication-title: N Engl J Med contributor: fullname: Belani – volume: 102 start-page: 82 year: 2010 end-page: 88 ident: bib21 article-title: When is cancer care cost-effective? publication-title: J Natl Cancer Inst contributor: fullname: Fang – volume: 355 start-page: 2542 year: 2006 end-page: 2550 ident: bib8 article-title: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer publication-title: N Engl J Med contributor: fullname: Perry – volume: 363 start-page: 1693 year: 2010 end-page: 1703 ident: bib46 article-title: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer publication-title: N Engl J Med contributor: fullname: Camidge – volume: 11 start-page: 90 year: 2006 end-page: 95 ident: bib43 article-title: Do oncologists believe new cancer drugs offer good value? publication-title: Oncologist contributor: fullname: Neumann – volume: 25 start-page: 5570 year: 2007 end-page: 5577 ident: bib24 article-title: Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database publication-title: J Clin Oncol contributor: fullname: Belani – volume: 14 start-page: 565 year: 2008 end-page: 571 ident: bib18 article-title: Metastatic non-small cell lung cancer: costs associated with disease progression publication-title: Am J Manag Care contributor: fullname: Kim – volume: 25 start-page: 180 year: 2007 end-page: 186 ident: bib12 article-title: Cost of cancer care: issues and implications publication-title: J Clin Oncol contributor: fullname: Schulman – volume: 10 start-page: 252 year: 2009 end-page: 256 ident: bib49 article-title: Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer publication-title: Clin Lung Cancer contributor: fullname: Socinski – volume: 11 start-page: 121 year: 2010 end-page: 128 ident: bib10 article-title: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial publication-title: Lancet Oncol contributor: fullname: Yatabe – volume: 4 start-page: 1450 year: 2009 end-page: 1454 ident: bib47 article-title: ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer publication-title: J Thorac Oncol contributor: fullname: Camidge – volume: 69 start-page: S18 year: 2010 end-page: S23 ident: bib16 article-title: Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany publication-title: Lung Cancer contributor: fullname: Walzer – volume: 5 start-page: 260 year: 2010 end-page: 274 ident: bib7 article-title: Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care publication-title: J Thorac Oncol contributor: fullname: Ellis – volume: 12 start-page: 80 year: 2009 end-page: 87 ident: bib35 article-title: An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard publication-title: Value Health contributor: fullname: Zenios – volume: 5 start-page: 1815 year: 2010 end-page: 1820 ident: bib48 article-title: Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaive patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116 publication-title: J Thorac Oncol contributor: fullname: Bradford – volume: 21 start-page: 3016 year: 2003 end-page: 3024 ident: bib50 article-title: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group publication-title: J Clin Oncol contributor: fullname: von Pawel – volume: 10 start-page: 1318 year: 2004 end-page: 1325 ident: bib28 article-title: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients publication-title: Clin Cancer Res contributor: fullname: Alberola – volume: 128 start-page: 452 year: 2005 end-page: 462 ident: bib3 article-title: Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003 publication-title: Chest contributor: fullname: Aubry – volume: 361 start-page: 947 year: 2009 end-page: 957 ident: bib45 article-title: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma publication-title: N Engl J Med contributor: fullname: Thongprasert – volume: 317 start-page: 771 year: 1998 end-page: 775 ident: bib32 article-title: Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews publication-title: BMJ contributor: fullname: Welch – volume: 30 start-page: 12 year: 2000 end-page: 21 ident: bib14 article-title: The principles of the Belmont report revisited publication-title: Hastings Cent Rep contributor: fullname: Cassell – volume: 6 start-page: 12 year: 2010 end-page: 18 ident: bib42 article-title: Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting publication-title: J Oncol Pract contributor: fullname: Kolodziej – volume: 26 start-page: 3543 year: 2008 end-page: 3551 ident: bib53 article-title: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer publication-title: J Clin Oncol contributor: fullname: von Pawel – volume: 21 start-page: v232 year: 2010 end-page: v243 ident: bib15 article-title: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference publication-title: Ann Oncol contributor: fullname: Aapro – volume: 27 start-page: 1394 year: 2009 end-page: 1400 ident: bib22 article-title: First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy publication-title: J Clin Oncol contributor: fullname: Usui – volume: 5 start-page: 1953 year: 2010 end-page: 1957 ident: bib19 article-title: Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer publication-title: J Thorac Oncol contributor: fullname: Mittmann – volume: 66 start-page: 282 year: 2009 end-page: 286 ident: bib25 article-title: Treatment of advanced non-small-cell lung cancer in the elderly publication-title: Lung Cancer contributor: fullname: Rossi – volume: 15 start-page: 1048 year: 2004 end-page: 1055 ident: bib54 article-title: Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial publication-title: Ann Oncol contributor: fullname: Georgatou – volume: 136 start-page: 243 year: 2002 end-page: 246 ident: bib34 article-title: Medical professionalism in the new millennium: a physician charter publication-title: Ann Intern Med – volume: 106 start-page: 861 year: 1994 end-page: 865 ident: bib4 article-title: Chemotherapy vs supportive care in advanced non-small-cell lung cancer publication-title: Chest contributor: fullname: Preatoni – volume: 461 start-page: 336 year: 2009 end-page: 339 ident: bib13 article-title: Health economics: Life in the balance publication-title: Nature contributor: fullname: Cressey – volume: 311 start-page: 899 year: 1995 end-page: 909 ident: bib5 article-title: a meta-analysis using updated data on individual patients from 52 randomised clinical trials publication-title: BMJ – volume: 135 start-page: 1061 year: 2009 end-page: 1068 ident: bib30 article-title: Informed consent for clinical research involving patients with chest disease in the United States publication-title: Chest contributor: fullname: Luce – volume: 15 start-page: 321 year: 2009 end-page: 326 ident: bib31 article-title: The role of palliative care in the lung cancer patient: can we improve quality while limiting futile care? publication-title: Curr Opin Pulm Med contributor: fullname: Zimmermann – volume: 101 start-page: 1044 year: 2009 end-page: 1048 ident: bib37 article-title: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question publication-title: J Natl Cancer Inst contributor: fullname: Grady – volume: 11 start-page: 149 year: 2010 end-page: 159 ident: bib26 article-title: The emerging role of biomarkers in advanced non-small-cell lung cancer publication-title: Clin Lung Cancer contributor: fullname: Socinski – volume: 69 start-page: S24 year: 2010 end-page: S30 ident: bib17 article-title: Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC) publication-title: Lung Cancer contributor: fullname: Heigener – volume: 9 start-page: 39 year: 2009 ident: bib33 article-title: Disclosure of cancer diagnosis and quality of life in cancer patients: should it be the same everywhere? publication-title: BMC Cancer contributor: fullname: Mohagheghi – year: 2010 ident: bib2 article-title: El cáncer en España.com – volume: 57 start-page: 43 year: 2007 end-page: 66 ident: bib1 article-title: Cancer statistics, 2007 publication-title: CA Cancer J Clin contributor: fullname: Ward – volume: 27 start-page: 113 year: 2009 end-page: 125 ident: bib20 article-title: Economics of treatments for non-small cell lung cancer publication-title: Pharmacoeconomics contributor: fullname: Hejblum – volume: 9 start-page: 39 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib33 article-title: Disclosure of cancer diagnosis and quality of life in cancer patients: should it be the same everywhere? publication-title: BMC Cancer doi: 10.1186/1471-2407-9-39 contributor: fullname: Montazeri – volume: 136 start-page: 243 year: 2002 ident: 10.1016/j.cllc.2011.06.007_bib34 article-title: Medical professionalism in the new millennium: a physician charter publication-title: Ann Intern Med doi: 10.7326/0003-4819-136-3-200202050-00012 – volume: 346 start-page: 92 year: 2002 ident: 10.1016/j.cllc.2011.06.007_bib6 article-title: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa011954 contributor: fullname: Schiller – volume: 362 start-page: 2380 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib9 article-title: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR publication-title: N Engl J Med doi: 10.1056/NEJMoa0909530 contributor: fullname: Maemondo – volume: 363 start-page: 1693 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib46 article-title: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1006448 contributor: fullname: Kwak – volume: 317 start-page: 771 year: 1998 ident: 10.1016/j.cllc.2011.06.007_bib32 article-title: Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews publication-title: BMJ doi: 10.1136/bmj.317.7161.771 contributor: fullname: Silvestri – volume: 66 start-page: 282 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib25 article-title: Treatment of advanced non-small-cell lung cancer in the elderly publication-title: Lung Cancer doi: 10.1016/j.lungcan.2009.08.006 contributor: fullname: Gridelli – volume: 24 start-page: 416 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib40 article-title: Prioritization of chemotherapy drugs in the Catalan hospital system: a qualitative case study] publication-title: Gac Sanit doi: 10.1016/j.gaceta.2010.05.007 contributor: fullname: Prades – volume: 25 start-page: 180 year: 2007 ident: 10.1016/j.cllc.2011.06.007_bib12 article-title: Cost of cancer care: issues and implications publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.6081 contributor: fullname: Meropol – volume: 69 start-page: S24 issue: suppl 1 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib17 article-title: Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC) publication-title: Lung Cancer doi: 10.1016/S0169-5002(10)70135-5 contributor: fullname: Stanisic – volume: 12 start-page: 80 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib35 article-title: An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard publication-title: Value Health doi: 10.1111/j.1524-4733.2008.00401.x contributor: fullname: Lee – volume: 30 start-page: 12 year: 2000 ident: 10.1016/j.cllc.2011.06.007_bib14 article-title: The principles of the Belmont report revisited publication-title: Hastings Cent Rep doi: 10.2307/3527640 contributor: fullname: Cassell – volume: 13 start-page: 1539 year: 2002 ident: 10.1016/j.cllc.2011.06.007_bib52 article-title: Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial publication-title: Ann Oncol doi: 10.1093/annonc/mdf332 contributor: fullname: Rosell – volume: 128 start-page: 452 year: 2005 ident: 10.1016/j.cllc.2011.06.007_bib3 article-title: Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003 publication-title: Chest doi: 10.1378/chest.128.1.452 contributor: fullname: Yang – volume: 10 start-page: 1318 year: 2004 ident: 10.1016/j.cllc.2011.06.007_bib28 article-title: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-03-0156 contributor: fullname: Rosell – volume: 20 start-page: 1249 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib51 article-title: Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdn774 contributor: fullname: Tan – volume: 15 start-page: 321 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib31 article-title: The role of palliative care in the lung cancer patient: can we improve quality while limiting futile care? publication-title: Curr Opin Pulm Med doi: 10.1097/MCP.0b013e32832b8a5d contributor: fullname: Freedman – volume: 11 start-page: 90 year: 2006 ident: 10.1016/j.cllc.2011.06.007_bib43 article-title: Do oncologists believe new cancer drugs offer good value? publication-title: Oncologist doi: 10.1634/theoncologist.11-2-90 contributor: fullname: Nadler – volume: 4 start-page: 1450 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib47 article-title: ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3181c4dedb contributor: fullname: Solomon – volume: 11 start-page: 121 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib10 article-title: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(09)70364-X contributor: fullname: Mitsudomi – volume: 355 start-page: 2542 year: 2006 ident: 10.1016/j.cllc.2011.06.007_bib8 article-title: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa061884 contributor: fullname: Sandler – volume: 135 start-page: 1061 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib30 article-title: Informed consent for clinical research involving patients with chest disease in the United States publication-title: Chest doi: 10.1378/chest.08-2621 contributor: fullname: Luce – volume: 69 start-page: 272 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib29 article-title: KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies publication-title: Lung Cancer doi: 10.1016/j.lungcan.2009.11.020 contributor: fullname: Mao – volume: 21 start-page: 3016 year: 2003 ident: 10.1016/j.cllc.2011.06.007_bib50 article-title: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group publication-title: J Clin Oncol doi: 10.1200/JCO.2003.12.046 contributor: fullname: Fossella – volume: 28 start-page: 1835 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib55 article-title: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2009.26.1321 contributor: fullname: Scagliotti – volume: 15 start-page: 1048 year: 2004 ident: 10.1016/j.cllc.2011.06.007_bib54 article-title: Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial publication-title: Ann Oncol doi: 10.1093/annonc/mdh260 contributor: fullname: Stathopoulos – volume: 27 start-page: 6251 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib38 article-title: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2009.23.5622 contributor: fullname: Azzoli – volume: 27 start-page: 113 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib20 article-title: Economics of treatments for non-small cell lung cancer publication-title: Pharmacoeconomics doi: 10.2165/00019053-200927020-00003 contributor: fullname: Chouaid – volume: 21 start-page: v232 issue: suppl 5 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib15 article-title: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference publication-title: Ann Oncol doi: 10.1093/annonc/mdq194 contributor: fullname: Roila – volume: 461 start-page: 336 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib13 article-title: Health economics: Life in the balance publication-title: Nature doi: 10.1038/461336a contributor: fullname: Cressey – volume: 57 start-page: 43 year: 2007 ident: 10.1016/j.cllc.2011.06.007_bib1 article-title: Cancer statistics, 2007 publication-title: CA Cancer J Clin doi: 10.3322/canjclin.57.1.43 contributor: fullname: Jemal – volume: 27 start-page: 1394 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib22 article-title: First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy publication-title: J Clin Oncol doi: 10.1200/JCO.2008.18.7658 contributor: fullname: Inoue – volume: 5 start-page: 1953 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib19 article-title: Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3181f77a6a contributor: fullname: Jang – volume: 26 start-page: 3543 year: 2008 ident: 10.1016/j.cllc.2011.06.007_bib53 article-title: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.0375 contributor: fullname: Scagliotti – volume: 5 start-page: 1815 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib48 article-title: Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaive patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3181ee820c contributor: fullname: Casey – volume: 5 start-page: 1529 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib23 article-title: Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3181e9a00f contributor: fullname: Rasco – volume: 11 start-page: 149 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib26 article-title: The emerging role of biomarkers in advanced non-small-cell lung cancer publication-title: Clin Lung Cancer doi: 10.3816/CLC.2010.n.019 contributor: fullname: Socinski – volume: 12 start-page: 493 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib44 article-title: Controversies on the management of clinical situations with low therapeutic effectiveness in oncology publication-title: Clin Transl Oncol doi: 10.1007/s12094-010-0542-4 contributor: fullname: Exposito – volume: 311 start-page: 899 year: 1995 ident: 10.1016/j.cllc.2011.06.007_bib5 article-title: a meta-analysis using updated data on individual patients from 52 randomised clinical trials publication-title: BMJ doi: 10.1136/bmj.311.7010.899 – volume: 25 start-page: 2747 year: 2007 ident: 10.1016/j.cllc.2011.06.007_bib27 article-title: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.7915 contributor: fullname: Cobo – volume: 361 start-page: 947 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib45 article-title: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa0810699 contributor: fullname: Mok – volume: 5 start-page: 260 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib7 article-title: Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3181c6f035 contributor: fullname: Goffin – volume: 15 start-page: 4493 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib11 article-title: Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-0391 contributor: fullname: Morita – volume: 101 start-page: 1044 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib37 article-title: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp177 contributor: fullname: Fojo – volume: 102 start-page: 82 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib21 article-title: When is cancer care cost-effective? publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp472 contributor: fullname: Greenberg – volume: 10 start-page: 252 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib49 publication-title: Clin Lung Cancer doi: 10.3816/CLC.2009.n.035 contributor: fullname: Patel – year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib39 – volume: 106 start-page: 861 year: 1994 ident: 10.1016/j.cllc.2011.06.007_bib4 article-title: Chemotherapy vs supportive care in advanced non-small-cell lung cancer publication-title: Chest doi: 10.1378/chest.106.3.861 contributor: fullname: Marino – volume: 69 start-page: S18 issue: suppl 1 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib16 article-title: Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany publication-title: Lung Cancer doi: 10.1016/S0169-5002(10)70134-3 contributor: fullname: Bischoff – volume: 25 start-page: 5570 year: 2007 ident: 10.1016/j.cllc.2011.06.007_bib24 article-title: Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database publication-title: J Clin Oncol doi: 10.1200/JCO.2007.12.5435 contributor: fullname: Owonikoko – volume: 28 start-page: 911 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib56 article-title: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.21.9618 contributor: fullname: Lynch – volume: 14 start-page: 565 year: 2008 ident: 10.1016/j.cllc.2011.06.007_bib18 article-title: Metastatic non-small cell lung cancer: costs associated with disease progression publication-title: Am J Manag Care contributor: fullname: Fox – volume: 6 start-page: 12 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib42 article-title: Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting publication-title: J Oncol Pract doi: 10.1200/JOP.091058 contributor: fullname: Neubauer – volume: 373 start-page: 1525 year: 2009 ident: 10.1016/j.cllc.2011.06.007_bib36 article-title: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial publication-title: Lancet doi: 10.1016/S0140-6736(09)60569-9 contributor: fullname: Pirker – volume: 15 start-page: 43 issue: suppl 1 year: 2010 ident: 10.1016/j.cllc.2011.06.007_bib41 article-title: Ethical issues in patient-physician communication about therapy for cancer: professional responsibilities of the oncologist publication-title: Oncologist doi: 10.1634/theoncologist.2010-S1-43 contributor: fullname: Wenger |
| SSID | ssj0026312 |
| Score | 1.9521462 |
| Snippet | Abstract Metastatic non–small-cell lung cancer is generally not considered to be curable, and the overall 5-year survival rate is less than 1%. Despite this... Metastatic non–small-cell lung cancer is generally not considered to be curable, and the overall 5-year survival rate is less than 1%. Despite this poor... Metastatic non-small-cell lung cancer is generally not considered to be curable, and the overall 5-year survival rate is less than 1%. Despite this poor... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 335 |
| SubjectTerms | Carcinoma, Non-Small-Cell Lung - economics Carcinoma, Non-Small-Cell Lung - secondary Carcinoma, Non-Small-Cell Lung - therapy Costs Delivery of Health Care - economics Delivery of Health Care - ethics Economics Ethics Health care costs Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - economics Lung Neoplasms - secondary Lung Neoplasms - therapy Non–small-cell lung cancer Pulmonary/Respiratory |
| Title | Costs and Ethical Issues Related to First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer: Considerations From a Public Healthcare System Perspective |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S1525730411001525 https://dx.doi.org/10.1016/j.cllc.2011.06.007 https://www.ncbi.nlm.nih.gov/pubmed/21816680 https://search.proquest.com/docview/902085878 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtZ3NjtMwEMet7iIBFwQLLOVLPnBbBSVxPrlBabWHpQdaJMTFcvwhddVtYNPceQcegHfjSZixnaRltQiQuESRpTqJ5ld7PP7PmJAXDA9BErIIqrKUQcISFQhTwiolUSZhupR5gcnJp4t8_rF4O02mo1FX4HFo-6-WhjawNWbO_oW1-06hAe7B5nAFq8P1j-w-qZutq7tspexYSsMesOdkb-BegrM5W4HPF5yhg7nsheaohdFbgRlGK3kyB5fQ6yDY4kKs18EEo3xnLcoEkBR7vGR33KfX080wV0X4UKDPcLLSMlcX3crtdzI7-woJXXbmGnuXtvc-TFDD8jt4g4LiSyfrrcWXdnWxE7C1zM1bp5f2sYV24zdZak-_6iO10V5go8-42ROE4nFNAYxKLgihXVsJgzZWXN4b1eMdeneHaObKo_jZnrliUVcmEhfTOH8p12vpC73irlU-TJu9mHGB74SvhNX38P6A3Ihh2MNR91P6vl_-Z8ztvXdf4FO4nNrw1-dc5yZdtwyy7tDyLrnj1zH0tQPwHhnpzRG51aW5N0fk5juv2rhPvlsmKTBJPZPUMUk9k3Rb04FJ2jNJa0MHJikw-ePrt4FGijRSR-Mrus8iRRapoI5FOrBIHYt0h8UH5MNsupycBv5gkEAmUbgNhKzAVWe5NGmosyjLTKQyFYdKGVWlVRXZArxaClPFWaqzLIlkqSpjCmZ0GYfsITnc1Bv9iFATVaaMq0InUieZkkKZKpJRHMZChCxVY3LS2YF_dvVfeCeMPOdoNY5W41Ydmo9J3pmKd5nNMBfrxg8QDY94E_OQX2FmTNL-l973dT4tByJ_-0TaEcFhYsDdPrHRddvw0h6_W-TFmBw7UvoPQLc-y4rw8T8-9Am5Pfxhn5LD7WWrn5GDRrXPLfI_AYgj6BY |
| link.rule.ids | 315,782,786,27933,27934 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Costs+and+Ethical+Issues+Related+to+First-Line+Treatment+of+Metastatic+Non%E2%80%93Small-Cell+Lung+Cancer%3A+Considerations+From+a+Public+Healthcare+System+Perspective&rft.jtitle=Clinical+lung+cancer&rft.au=Bosch-Barrera%2C+Joaquim&rft.au=Quer%2C+Nuria&rft.au=Brunet%2C+Joan&rft.date=2011-11-01&rft.pub=Elsevier+Inc&rft.issn=1525-7304&rft.eissn=1938-0690&rft.volume=12&rft.issue=6&rft.spage=335&rft.epage=340&rft_id=info:doi/10.1016%2Fj.cllc.2011.06.007&rft.externalDocID=S1525730411001525 |
| thumbnail_m | http://sdu.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F15257304%2FS1525730411X00062%2Fcov150h.gif |